Chemomab Therapeutics (CMMB) Net Cash Flow (QoQ) (2018 - 2023)
Chemomab Therapeutics (CMMB) Net Cash Flow (QoQ) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 111.40% |
| Sep 30, 2023 | 88.18% |
| Jun 30, 2023 | -243.33% |
| Mar 31, 2023 | 160.84% |
| Dec 31, 2022 | 223.78% |
| Sep 30, 2022 | 121.71% |
| Jun 30, 2022 | -197.37% |
| Mar 31, 2022 | 94.11% |
| Dec 31, 2021 | -194.77% |
| Sep 30, 2021 | 40.13% |
| Jun 30, 2021 | -127.49% |
| Mar 31, 2021 | 4,773.77% |
| Dec 31, 2020 | -177.16% |
| Sep 30, 2020 | -116.15% |
| Jun 30, 2020 | 256.22% |
| Mar 31, 2020 | 74.87% |
| Dec 31, 2019 | -50.53% |
| Sep 30, 2019 | 26.65% |
| Jun 30, 2019 | -120.83% |
| Mar 31, 2019 | 702.00% |